Latest KROS reports update at 2024-02-28: 2023 ∙ 2022 ∙ 2021

Keros Therapeutics KROS

$ 58.24 -0.75%

Keros Therapeutics Financial Statements 2011-2024 | KROS

Annual Financial Statements Keros Therapeutics

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Market Cap	2.01 B	1.49 B	1.37 B	1.23 B	-	-	-	-	-	-	-	-	-
Shares	29.4 M	25.2 M	23.3 M	21.6 M	-	-	-	-	-	-	-	-	-
Historical Prices	68.4	59.2	58.5	70.5	-	-	-	-	-	-	-	-	-
Net Income	-153 M	-105 M	-58.7 M	-45.4 M	-12.3 M	-1.34 M	-	-	-	-	-	-	-
Revenue	151 K	-	20.1 M	-	10 M	10 M	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-170 M	-115 M	-56.4 M	-46.7 M	-10.6 M	-	-	-	-	-	-	-	-
Interest Expense	-206 K	-613 K	-383 K	160 K	241 K	-	-	-	-	-	-	-	-
EBITDA	-169 M	-114 M	-56 M	-45.2 M	-10.4 M	-1.54 M	-	-	-	-	-	-	-
Operating Expenses	170 M	115 M	76.5 M	46.7 M	-	-	-	-	-	-	-	-	-
General and Administrative Expenses	34.8 M	27.5 M	21.3 M	12.8 M	3.18 M	1.58 M	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Income Statement Keros Therapeutics

	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Shares	29.7 M	29.6 M	28.4 M	27.5 M	25.5 M	24.1 M	24 M	24 M	23.4 M	23.3 M	23.2 M	23.2 M	20.2 M	17.6 M	2.48 M	2.43 M	2.34 M	2.29 M	2.26 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-39.4 M	-37.5 M	-35.8 M	-	-23.5 M	-27.3 M	-24.2 M	-	-20.3 M	-15.6 M	-15.9 M	-	-12 M	-10.8 M	-11.9 M	-	-3.55 M	-2.85 M	-3.18 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Revenue	8 K	-	-	-	-	-	-	-	-	100 K	-	-	-	-	-	-	2.5 M	2.5 M	2.5 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-43.3 M	-41.3 M	-38.9 M	-	-28 M	-30.7 M	-24.1 M	-	-20.2 M	-15.5 M	-15.8 M	-	-11.9 M	-10.9 M	-10.5 M	-	-2.33 M	-2.65 M	-2.86 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expense	3.84 M	3.83 M	3.06 M	-	762 K	86 K	-59 K	-	-137 K	-80 K	-65 K	-	-86 K	158 K	-68 K	-	15 K	69 K	101 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA	-	-	-38.7 M	-	-27.4 M	-30.7 M	-24 M	-	-19.9 M	-15.5 M	-15.7 M	-	-11.7 M	-10.8 M	-10.4 M	-	-2.18 M	-2.56 M	-2.81 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	43.3 M	41.3 M	38.9 M	-	28 M	30.7 M	24.1 M	-	20.2 M	15.6 M	15.8 M	-	11.9 M	10.9 M	10.5 M	-	4.83 M	5.15 M	5.36 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General and Administrative Expenses	9.15 M	8.8 M	7.78 M	-	6.94 M	7.45 M	6.05 M	-	5.36 M	5.66 M	4.27 M	-	3.55 M	3.65 M	1.98 M	-	972 K	654 K	491 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency